Efficacy of Intravenous Immunoglobulin in Multifocal Motor Neuropathy

• Published in: Annals of the New York Academy of Sciences 2007-09, Vol.1110 (1), p.248-255
• Main Authors: LEGER, JEAN-MARC, VARGAS, STEVEN, LIEVENS, ISABELLE
• Format: Article
• Language: English
• Subjects: anti-GM1 antibodies; Clinical Trials as Topic; conduction block; Humans; Immunoglobulins, Intravenous - therapeutic use; Immunotherapy; intravenous immunoglobulins (IVIg); Multifocal motor neuropathy; Polyneuropathies - immunology; Polyneuropathies - pathology; Polyneuropathies - therapy; Time Factors
• ISSN: 0077-8923; 1749-6632; 1930-6547
• DOI: 10.1196/annals.1423.026

:  Multifocal motor neuropathy is a distinct entity, whose treatment differs from that of other chronic immune‐mediated neuropathies, mainly chronic inflammatory demyelinating polyradiculoneuropathy, and its variant, multifocal acquired demyelinating sensory and motor neuropathy, although they share some electrophysiological characteristics. From the first descriptions, intravenous immunoglobulins (IVIg) have been considered to be the gold standard of treatment for multifocal motor neuropathy. However, if the effectiveness of IVIg has been confirmed by several randomized, double‐blind, placebo‐controlled trials, only a few patients experience persistent improvement after a single or few courses of therapy, and the long‐term efficacy of IVIg in this disease is currently debated. Consequently, there is a need for new therapeutic strategies that focus on the effects and the costs of this therapy over long‐term follow‐up.